8-K: Henry Schein Reports Strong Q1 2026 Results, Reaffirms Guidance

Henry Schein announced robust first-quarter 2026 financial results, with total net sales up 6.3% and non-GAAP diluted EPS increasing to $1.32, while reaffirming its full-year guidance.

Summary

• Henry Schein reported first-quarter 2026 results with total net sales of $3.4 billion, a 6.3% increase year-over-year.
• GAAP diluted EPS was $0.92, up from $0.88 in Q1 2025.
• Non-GAAP diluted EPS reached $1.32, an increase from $1.15 in Q1 2025.
• Adjusted EBITDA was $289 million, up from $259 million in Q1 2025.
• The company reaffirmed its 2026 financial guidance for sales, non-GAAP diluted EPS, and Adjusted EBITDA.
• Value creation initiatives are expected to deliver over $200 million in operating income improvement within a few years, with a $125 million run-rate by year-end 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong top-line growth and significant improvements in non-GAAP metrics, alongside reaffirmed guidance and clear value creation targets.

Positives

• Total net sales increased by 6.3% to $3.4 billion in Q1 2026.
• Internal sales growth was 2.5%, driven by strong performance in Global Dental Distribution merchandise (9.0% increase) and equipment (8.6% increase).
• Global Value-Added Services saw a significant 10.6% increase, with 7.8% internal sales growth.
• Non-GAAP diluted EPS improved by 14.8% to $1.32.
• Adjusted EBITDA grew by 11.6% to $289 million.
• The company is on track to achieve over $200 million in operating income improvement from value creation initiatives.
• Share repurchases totaled $125 million in Q1 2026, with $655 million remaining authorization.

Negatives

• GAAP net income attributable to Henry Schein, Inc. decreased slightly by 2.3% to $107 million.
• GAAP diluted EPS saw a modest increase of 4.5% to $0.92, but the non-GAAP figures show stronger growth.
• Restructuring and related costs were $12 million in Q1 2026, compared to $25 million in Q1 2025, indicating ongoing restructuring efforts.

Risks

• Dependence on third parties for product manufacturing and supply.
• Risks related to achieving strategic growth objectives and value creation initiatives.
• Challenges associated with acquisitions and joint ventures, including achieving anticipated synergies.
• Cybersecurity risks, including potential cyberattacks or data security breaches.
• Highly competitive and consolidating market, including competition from online commerce sites.
• Political, economic, and regulatory influences on the healthcare industry.
• Supply chain disruptions and increases in shipping and energy costs.
• Global economic and political conditions, including inflation, recession, and currency fluctuations.

Future Outlook

Henry Schein reaffirmed its 2026 financial guidance, expecting total sales growth of approximately 3% to 5% over 2025, non-GAAP diluted EPS between $5.23 to $5.37, and mid-single digit growth in Adjusted EBITDA compared to 2025. The company anticipates value creation initiatives to deliver over $200 million of operating income improvement within the next few years, with a $125 million run-rate by the end of 2026, contributing to high-single digit to low-double digit earnings growth.

Management Comments

• "I am pleased with our strong first quarter results that reflect continuing momentum from the second half of last year as we grow market share and expand gross margins."
• "Our growth outlook, combined with the progress made on value-creation initiatives and a strong start to the year, reinforces my confidence that we will deliver on our 2026 financial guidance."
• "I am committed to the Companys goal of achieving greater than $200 million of annual operating income improvement within the next few years, with a $125 million run-rate by the end of 2026."
• "These initiatives, along with continued execution of our strategic plan, will contribute to us achieving high-single digit to low-double digit earnings growth in the coming years."
• "As we look ahead, Im excited by the significant opportunities to accelerate growth through the use of technology, improve operational execution, and become a more agile company."

Industry Context

StockSavvy.ai notes that Henry Schein's performance in Q1 2026, with solid sales growth and improved non-GAAP EPS, aligns with a broader trend of healthcare solutions providers benefiting from increased demand for essential medical and dental supplies and services. The company's focus on value creation initiatives and technology acceleration is a strategic response to evolving market dynamics and competitive pressures within the healthcare distribution sector.

Comparison to Industry Standards

• Henry Schein's Q1 2026 total net sales growth of 6.3% outpaces the general economic growth in many developed markets, suggesting strong performance within its specific healthcare distribution niche.
• The internal sales growth of 2.5% indicates solid organic expansion, which is a key benchmark for mature companies in the distribution sector. Competitors like Cardinal Health and McKesson also focus on organic growth, but specific comparable figures for Q1 2026 are not detailed here.
• The company's reaffirmation of full-year guidance suggests a stable outlook, which is positive in an environment where many companies are facing economic uncertainties. This contrasts with some sectors experiencing downward revisions.
• The focus on value creation initiatives aiming for over $200 million in operating income improvement is a significant strategic undertaking, comparable to efficiency drives seen at other large distributors aiming to offset margin pressures.

Stakeholder Impact

• Shareholders: Positive impact from reaffirmed guidance, share repurchases, and expected operating income improvement, potentially leading to increased shareholder value.
• Customers: Continued provision of healthcare solutions, with potential for improved efficiency and outcomes through technology and operational enhancements.
• Suppliers: Continued business relationship, with potential for increased order volumes due to sales growth.
• Employees: Potential for continued employment and growth opportunities as the company focuses on operational execution and technology adoption.

Next Steps

• Continue execution of the strategic plan.
• Accelerate growth through the use of technology.
• Improve operational execution.
• Become a more agile company.
• Achieve $125 million run-rate for value creation initiatives by year-end 2026.

Key Dates

Recommendation

The company delivered expected results with solid sales growth and improved non-GAAP metrics, reaffirming full-year guidance. While positives exist, the slight dip in GAAP net income and ongoing restructuring costs, coupled with significant risks outlined, suggest a 'hold' rating until further clarity on the impact of value creation initiatives and broader economic conditions emerges.

Keywords

Henry Schein, Healthcare Solutions, Dental Distribution, Medical Distribution, Financial Results, Q1 2026, EPS, Sales Growth